Cargando…
GSK-3β Controls Osteogenesis through Regulating Runx2 Activity
Despite accumulated knowledge of various signalings regulating bone formation, the molecular network has not been clarified sufficiently to lead to clinical application. Here we show that heterozygous glycogen synthase kinase-3β (GSK-3β)-deficient mice displayed an increased bone formation due to an...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950686/ https://www.ncbi.nlm.nih.gov/pubmed/17786208 http://dx.doi.org/10.1371/journal.pone.0000837 |
_version_ | 1782134567951400960 |
---|---|
author | Kugimiya, Fumitaka Kawaguchi, Hiroshi Ohba, Shinsuke Kawamura, Naohiro Hirata, Makoto Chikuda, Hirotaka Azuma, Yoshiaki Woodgett, James R. Nakamura, Kozo Chung, Ung-il |
author_facet | Kugimiya, Fumitaka Kawaguchi, Hiroshi Ohba, Shinsuke Kawamura, Naohiro Hirata, Makoto Chikuda, Hirotaka Azuma, Yoshiaki Woodgett, James R. Nakamura, Kozo Chung, Ung-il |
author_sort | Kugimiya, Fumitaka |
collection | PubMed |
description | Despite accumulated knowledge of various signalings regulating bone formation, the molecular network has not been clarified sufficiently to lead to clinical application. Here we show that heterozygous glycogen synthase kinase-3β (GSK-3β)-deficient mice displayed an increased bone formation due to an enhanced transcriptional activity of Runx2 by suppressing the inhibitory phosphorylation at a specific site. The cleidocranial dysplasia in heterozygous Runx2-deficient mice was significantly rescued by the genetic insufficiency of GSK-3β or the oral administration of lithium chloride, a selective inhibitor of GSK-3β. These results establish GSK-3β as a key attenuator of Runx2 activity in bone formation and as a potential molecular target for clinical treatment of bone catabolic disorders like cleidocranial dysplasia. |
format | Text |
id | pubmed-1950686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-19506862007-09-05 GSK-3β Controls Osteogenesis through Regulating Runx2 Activity Kugimiya, Fumitaka Kawaguchi, Hiroshi Ohba, Shinsuke Kawamura, Naohiro Hirata, Makoto Chikuda, Hirotaka Azuma, Yoshiaki Woodgett, James R. Nakamura, Kozo Chung, Ung-il PLoS One Research Article Despite accumulated knowledge of various signalings regulating bone formation, the molecular network has not been clarified sufficiently to lead to clinical application. Here we show that heterozygous glycogen synthase kinase-3β (GSK-3β)-deficient mice displayed an increased bone formation due to an enhanced transcriptional activity of Runx2 by suppressing the inhibitory phosphorylation at a specific site. The cleidocranial dysplasia in heterozygous Runx2-deficient mice was significantly rescued by the genetic insufficiency of GSK-3β or the oral administration of lithium chloride, a selective inhibitor of GSK-3β. These results establish GSK-3β as a key attenuator of Runx2 activity in bone formation and as a potential molecular target for clinical treatment of bone catabolic disorders like cleidocranial dysplasia. Public Library of Science 2007-09-05 /pmc/articles/PMC1950686/ /pubmed/17786208 http://dx.doi.org/10.1371/journal.pone.0000837 Text en Kugimiya et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Kugimiya, Fumitaka Kawaguchi, Hiroshi Ohba, Shinsuke Kawamura, Naohiro Hirata, Makoto Chikuda, Hirotaka Azuma, Yoshiaki Woodgett, James R. Nakamura, Kozo Chung, Ung-il GSK-3β Controls Osteogenesis through Regulating Runx2 Activity |
title | GSK-3β Controls Osteogenesis through Regulating Runx2 Activity |
title_full | GSK-3β Controls Osteogenesis through Regulating Runx2 Activity |
title_fullStr | GSK-3β Controls Osteogenesis through Regulating Runx2 Activity |
title_full_unstemmed | GSK-3β Controls Osteogenesis through Regulating Runx2 Activity |
title_short | GSK-3β Controls Osteogenesis through Regulating Runx2 Activity |
title_sort | gsk-3β controls osteogenesis through regulating runx2 activity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950686/ https://www.ncbi.nlm.nih.gov/pubmed/17786208 http://dx.doi.org/10.1371/journal.pone.0000837 |
work_keys_str_mv | AT kugimiyafumitaka gsk3bcontrolsosteogenesisthroughregulatingrunx2activity AT kawaguchihiroshi gsk3bcontrolsosteogenesisthroughregulatingrunx2activity AT ohbashinsuke gsk3bcontrolsosteogenesisthroughregulatingrunx2activity AT kawamuranaohiro gsk3bcontrolsosteogenesisthroughregulatingrunx2activity AT hiratamakoto gsk3bcontrolsosteogenesisthroughregulatingrunx2activity AT chikudahirotaka gsk3bcontrolsosteogenesisthroughregulatingrunx2activity AT azumayoshiaki gsk3bcontrolsosteogenesisthroughregulatingrunx2activity AT woodgettjamesr gsk3bcontrolsosteogenesisthroughregulatingrunx2activity AT nakamurakozo gsk3bcontrolsosteogenesisthroughregulatingrunx2activity AT chungungil gsk3bcontrolsosteogenesisthroughregulatingrunx2activity |